Nebivolol Al

Nebivolol, the active ingredient in Nebivolol Al, is a beta blocker presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Nebivolol Al as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective beta‑1 blocker used to manage conditions within the cardiovascular disease spectrum. Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. Essential hypertension: helps achieve guideline‑recommended blood‑pressure targets. High blood pressure: reduces cardiovascular risk by controlling both systolic and diastolic values.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion or rhinorrhea. - Bradycardia: heart rate slower than normal. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Symptomatic hypotension with risk of syncope. - Acute bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic dysfunction or elevated liver enzymes. - Cardiovascular collapse in the setting of overdose.

Before initiating Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Cardiovascular assessment: monitor heart rate and blood pressure regularly. - Renal impairment: use with caution and adjust dosing if necessary. - Hepatic disease: consider reduced clearance and monitor liver function. - Respiratory conditions: avoid in patients with active asthma or severe COPD. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Drug interaction review: assess concomitant medications for additive effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and severe bradycardia. - Clonidine abrupt withdrawal: may precipitate rebound hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: potential for enhanced hypotensive effect. - Diuretics: may increase orthostatic hypotension. - Antidiabetic agents: beta‑blockade can mask hypoglycaemia symptoms. - Antidepressants (SSRIs, SNRIs): may affect heart rate variability. - NSAIDs: can attenuate antihypertensive efficacy.